IAS 2011: iPrEx Shows PrEP is Durable [VIDEO]
- Details
- Category: HIV Prevention
- Published on Friday, 29 July 2011 00:00
- Written by Video
The effectiveness of biomedical approaches to prevent HIV infection was a key theme of the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011), held July 17-20, 2011, in Rome.
Among the major studies presented, Robert Grant from the Gladstone Institute of the University of California at San Francisco described final data from the iPrEx trial, which showed that pre-exposure prophylaxis (PrEP) using tenofovir/emtricitabine (Truvada) reduced new HIV infections by 42% overall, and by more than 90% among people who demonstrated good adherence.
IAS 2011: New Integrase Inhibitor Dolutegravir Looks Potent and Well-tolerated
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 26 July 2011 00:00
- Written by Liz Highleyman
The next-generation HIV integrase inhibitor dolutegravir (S/GSK1349572) suppressed HIV viral load as well as efavirenz (Sustiva) but caused fewer side effects in a study of treatment-naive patients, researchers reported at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) last week in Rome. 
IAS 2011: Doubt Remains if HIV Therapy Increases the Risk of Fragility Fractures
- Details
- Category: Bone Loss
- Published on Tuesday, 26 July 2011 00:00
- Written by Michael Carter
The relationship between HIV therapy and fracture risk is far from straightforward, U.S. research presented to the International AIDS Society conference in Rome suggests.
IAS 2011: Raltegravir Still Effective at 5 Years
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 26 July 2011 00:00
- Written by Merck
The sole approved integrase inhibitor, raltegravir (Isentress), continues to keep HIV suppressed for nearly 5 years in patients starting treatment for the first time, according to astudy presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) last week in Rome.
IAS 2011: HIV PrEP Effective for Heterosexuals, Discordant Couples
- Details
- Category: HIV Prevention
- Published on Tuesday, 26 July 2011 00:00
- Written by Paul Dalton
Two studies find that pre-exposure prophylaxis (PrEP) with tenofovir or tenofovir/emtricitabine reduces the risk of HIV infection among heterosexuals and serodiscordant couples, researchers reported at IAS 2011.
More Articles...
- IAS 2011: HIV Prevention -- A Women's Revolution [VIDEO]
- IAS 2011: New NNRTI Lersivirine Looks Good in Phase 2 Study
- IAS 2011: Cognitive Impairment is Common, but ART Reduces Risk
- HIV Drug Development News from IAS 2011 [VIDEO]
- IAS 2011: Randomized Trial Supports Earlier Treatment
- IAS 2011: Once-daily Elvitegravir Matches Twice-daily Raltegravir
- IAS 2011: The Proof is Here: HIV Treatment is HIV Prevention
- IAS 2011: Coronary Artery Calcification Linked to Bone Loss
- IAS 2011: Stakeholders Call for HIV Cure Research
- IAS 2011: HIV Treatment as Prevention: HPTN 052 Offers Proof [VIDEO]
Web Design and Development by